Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

By E. Romond, E. Perez, J. Bryant, V. Suman, C. Geyer, N. Davidson, E. Tan-chiu, S. Martino, S. Paik, P. Kaufman and 15 more. New England Journal of Medicine, 2005

5,515 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/d4b010de619440669aa7549d832671caa50e8e49

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Pathology and Forensic Medicine

Citations in the corpus

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. (2014, methodology): “Proportional hazards modeling was used to assess whether DFS or OS differed with respect to treatment, taking into account the stratification factors: study (B-31 v N9831), intended paclitaxel schedule (once every 3 weeks v once per week), number of positive nodes (zero to three v four to nine v 10 ”
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. (2012, neutral): “BCIRG 006, n = 3,222 [14] AC + T versus AC + TH +H versus TCaH 11% versus 19% versus 9% 0.”
A review on machine learning approaches and trends in drug discovery (2021, background): “For these patients, treatment with the drug trastuzumab (Herceptin) in addition to chemotherapy treatment can reduce the risk of recurrence to more than 50% [3].”
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. (2009, background): “Elevated HER-2 expression defines a subgroup with a poor prognosis; however, the responsiveness of this subgroup to trastuzumab improves outcomes (10).”
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, neutral): “FE100C 6 3 [35] CE1,8F 6 4 [13, 56] A (or E)/CMF 4/4 (–8) 3/4 [14, 71] AP/CMF 4/4 3/4 [37] DC 4 3 [53] AC/P(H) qwk 4/4 3/3 [76, 84] AC/D(H) 4/4 3/3 [84]”
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses (2008, background): “Treatment with trastuzumab improves the outcomes of women with HER2-positive breast cancer, both in the metastatic [4‐6] and adjuvant settings [ 7 , 8]. However primary/de-novo or secondary resistance to trastuzumab occurs in some patients.”
Tumor metastasis: mechanistic insights and clinical challenges (2006, background): “, and successful data in the adjuvant (lymph node–positive) setting have been reporte”